J
Julia Slotta-Huspenina
Researcher at Technische Universität München
Publications - 146
Citations - 10859
Julia Slotta-Huspenina is an academic researcher from Technische Universität München. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 36, co-authored 124 publications receiving 7901 citations. Previous affiliations of Julia Slotta-Huspenina include Ludwig Maximilian University of Munich.
Papers
More filters
Journal ArticleDOI
Differential diagnosis of cyclin D2+ mantle cell lymphoma based on fluorescence in situ hybridization and quantitative real-time-PCR
Leticia Quintanilla-Martinez,Julia Slotta-Huspenina,Ina Koch,Margit Klier,Eric D. Hsi,Laurence de Leval,Wolfram Klapper,Stefan Gesk,Reiner Siebert,Falko Fend +9 more
TL;DR: The authors show that the quantification of cyclin D2 mRNA levels but not its immunohistochemical detection may be a useful tool to distinguishcyclin D1-negative mantle cell lymphoma with cyclinD2 translocations from other small B-cell lymphomas.
Journal ArticleDOI
Expression analysis of LC3B and p62 indicates intact activated autophagy is associated with an unfavorable prognosis in colon cancer.
Monique Niklaus,Olivia Joan Adams,Sabina Berezowska,Inti Zlobec,Franziska Graber,Julia Slotta-Huspenina,Ulrich Nitsche,Robert D. Rosenberg,Mario P. Tschan,Rupert Langer +9 more
TL;DR: These specific expression patterns of LC3B and p62 pointing to different states of autophagy associated with diverging clinical outcomes highlighte the potential significance of basal Autophagy in CC biology.
Journal ArticleDOI
Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping
Moritz Jesinghaus,Katja Steiger,Julia Slotta-Huspenina,Enken Drecoll,Nicole Pfarr,Petra Meyer,Björn Konukiewitz,Marcus Bettstetter,Kathrin Wieczorek,Katja Ott,M. Feith,Rupert Langer,Wilko Weichert,Katja Specht,Melanie Boxberg +14 more
TL;DR: This study demarcates a prognostically unfavorable, “non-immunoreactive” CD3ilow / PD-L1low ESCC-subgroup, potentially forming the basis for an immune-based stratification of ESCC.
Journal ArticleDOI
Pharmacoproteomic characterisation of human colon and rectal cancer.
Martin Frejno,Martin Frejno,Riccardo Zenezini Chiozzi,Riccardo Zenezini Chiozzi,Mathias Wilhelm,Heiner Koch,Heiner Koch,Runsheng Zheng,Susan Klaeger,Susan Klaeger,Benjamin Ruprecht,Benjamin Ruprecht,Chen Meng,Karl Kramer,Anna Jarzab,Stephanie Heinzlmeir,Stephanie Heinzlmeir,Elaine C. Johnstone,Enric Domingo,Enric Domingo,David J. Kerr,Moritz Jesinghaus,Julia Slotta-Huspenina,Wilko Weichert,Stefan Knapp,Stephan M. Feller,Stephan M. Feller,Bernhard Kuster +27 more
TL;DR: Modelling the responses of 52 CRC cell lines to 577 drugs as a function of proteome profiles enabled predicting drug sensitivity for cell lines and patients, and MERTK was identified as a predictive marker for resistance towards MEK1/2 inhibitors and immunohistochemistry of 1,074 CRC tumours confirmed MertK as a prognostic survival marker.
Journal ArticleDOI
Multiple recurrent chromosomal breakpoints in mantle cell lymphoma revealed by a combination of molecular cytogenetic techniques.
Itziar Salaverria,Blanca Espinet,Ana Carrió,Dolors Costa,Laura Astier,Julia Slotta-Huspenina,Leticia Quintanilla-Martinez,Falko Fend,Francesc Solé,Dolors Colomer,Sergio Serrano,Rosa Miró,Sílvia Beà,Elias Campo +13 more
TL;DR: Mantle cell lymphoma does not have recurrent translocations other than t(11;14), but shows recurrent chromosomal breakpoints, leading to various balanced and unbalanced translocations.